Integra Lifesciences to Showcase Advanced Gene-Writing Technology at ASGCT 2025 Meeting

Integra Therapeutics Poised to Transform Cell Therapies with Advanced Gene-Writing Technology

Integra Therapeutics, a frontrunner in the field of gene-writing technology, prepares to unveil groundbreaking pre-clinical data at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans, scheduled for May 13 to 17, 2025. Dr. Avencia Sánchez-Mejías, CEO and Co-Founder, accentuates the importance of this presentation, highlighting the company’s innovative gene-writing platform that boasts double-digit editing efficiencies and multi-gene integration capabilities. These advancements are particularly aimed at enhancing cell therapies for oncological and autoimmune diseases, showcasing significant potential to revolutionize treatment methodologies in these challenging areas.

A key focus of Integra’s presentation will be its CAR-T cell technology, which has shown exceptional results in creating CAR-T cells that express complex CARs, including bispecific variants equipped with a kill switch. This innovation simplifies the production process while demonstrating improved efficacy in eliminating B-ALL tumor cells and addressing autoimmune conditions such as lupus and rheumatoid arthritis. The efficiency of these CAR-T cells positions Integra as a critical player in the evolving landscape of cell therapies, where precision and effectiveness are paramount for successful patient outcomes.

Further strengthening its competitive edge, Integra plans to highlight results from CAR-T cells generated using novel CRISPR-Cas12l nucleases in conjunction with its proprietary FiCAT platform, developed through a strategic collaboration with Caszyme. This combination offers enhanced efficiency over traditional CRISPR-Cas9 techniques, presenting a significant leap forward in gene-editing technologies. Among the anticipated presentations are topics such as the “Precise Gene Writing System for CAR-T cell therapy generation” and a “viral-free FiCAT gene writing platform for liver-directed in vivo applications,” both set for discussion on May 14, 2025. The FiCAT platform stands out for addressing critical challenges in gene editing, combining CRISPR-Cas nucleases with an engineered transposase for efficient, safe editing of both small regions and large genes in primary cells.

In addition to the advancements showcased, Integra's participation in the ASGCT meeting underscores the company's commitment to pioneering research that could redefine treatment paradigms in gene and cell therapy. By focusing on precision, safety, and efficiency, Integra positions itself as a leader in the biopharmaceutical industry, poised to make significant contributions to therapies for complex diseases. The anticipated data presentations are likely to attract attention from industry professionals, researchers, and potential collaborators eager to explore the implications of these innovative technologies.